FRAX486 ndinavir blocks TBK1- and IKKε-mediated activation

blocks TBK1- and IKKε-mediated activation of IRF3 and production of IFN-β

05%)-treated eyes show significant reduction of IOP between 2 and 7 hours after topical administration

CAS Number: 104931-56-8

Wardlaw AJ

18-trimethoxy-13-(methoxymethyl)-11-methyl-11-azahexacyclo[7

FRAX486 ndinavir blocks TBK1- and IKKε-mediated activationFRAX486 is a potent p21 activated kinase (PAK) inhibitor (IC50 values are 14, 33, 39 and 575 nM for PAK1, PAK2, PAK3 and PAK4 respectively). FRAX486 rescues seizures and behavioral abnormalities such as hyperactivity and repetitive movements, thereby supporting the hypothesis that a drug treatment that reverses the spine abnormalities can also treat neurological and behavioral symptoms. A single administration of FRAX486 is sufficient to rescue all of